Publications
CIBMTR Publication List
Since 1972, using CIBMTR data and statistical resources has resulted in more than 2,000 publications.
CIBMTR also makes its publication analysis datasets freely available to the public for secondary analysis while safeguarding participants' privacy and protecting confidential and proprietary data.
Browse Publications
2026 | Transplantation and Cellular Therapy
Impact of complete response on long-term survival in patients with relapsed or refractory large B‑cell lymphoma: A CIBMTR prospective study and SLR/meta-analysis.
Authors:
Ghobadi A, Anagnostou T, Azzi J, Hamadani M, Logan B, Ahmed S, Bharadwaj S, Baird JH, Jacobson C, Locke FL, Ulrickson M, Reagan PM, Hemmer MT, Hu ZH, Luo ZC, Wang HL, Jung AS, Nahas M, Best T, Beygi S, Pasquini MC
2026 | Journal of Cancer Survivorship
Visualizing health-related quality of life (HRQoL): Understanding comprehension of HRQoL graphs in the allogeneic hematopoietic cell transplant setting.
Authors:
Cusatis R, Kapfhammer M, Rein L, Szabo A, Reed-Thryselius S, Phelan R, Bingen K, Runaas L, Shaw BE, Flynn KE
2026 | Transplantation and Cellular Therapy
Response to "Revisiting allogeneic hematopoietic cell donor selection guidelines: Umbilical cord blood in the PTCy era".
Authors:
Shaffer BC, Spellman SR, Shaw BE, Jimenez Jimenez AM
2025 | Transplantation and Cellular Therapy
Impact of extramedullary disease at diagnosis on outcomes post allogeneic hematopoietic cell transplant in children and young adults with acute myeloid leukemia: A CIBMTR report.
Authors:
Rangarajan HG, Chellapandian D, Atshan R, Ahn KW, Kumar S, Knight TE, Leung W, Ganguly S, Williams KM, Shah NN, Bhatt NS, Lust H, Prestidge T, Brown VI, Hayashi RJ, Choe M, Saad A, Bidgoli A, Thakar MS, Wirk B, MacMillan ML, Lalefar NR, Hematti P, Schultz KR, Phillips CL, Mehta PA, Qayed M, Sharma A, Broglie L, Satwani P
2025 | Bone Marrow Transplantation
Identification and management of the backup donor: recommendations from the World Marrow Donor Association.
Authors:
Greco-Stewart V, Manor S, Pollichieni S, Kathke A, Rall G, Evseeva I, Johnson P, Martfeld A, Schuit M, Tistl I
2025 | Transplantation and Cellular Therapy
Higher HLA-DRB1 evolutionary divergence (HED) is associated with reduced relapse and improved survival after matched unrelated hematopoietic cell transplantation.
Authors:
Saultz JN, Bolon YT, Wang T, Spellman SR, Lee SJ, He M, Camacho-Bydume C, Krishna C, Chowell D, Shaffer BC, Hsu K, Paczesny S, Gadalla SM, Marsh SGE, Betts BC, Arrieta-Bolaños E
2025 | Blood Advances
Impact of age on graft-vs-host disease and overall survival in pediatric hematopoietic cell transplant recipients.
Authors:
Nishitani M, Graham RT, Wang T, DeVos JD, Lee SJ, Spellman SR, Kitko CL, MacMillan ML, DeFilipp Z, Gray AN, Williams KM, Takahashi T, Schoettler ML, Hashem H, Rangarajan HG, Prestidge T, Ringden O, Hamilton BK, Sharma A, Nusrat R, El Jurdi N, Bhatt NS, Duncan CN, Qayed M
2025 | Blood Advances
Validated clinical risk score for acute graft-versus-host disease in adult allogeneic hematopoietic cell transplantation.
Authors:
Ulschmid C, Li X, Wang T, Logan BR, Pidala JA, MacMillan ML, Kitko CL, Lee SJ, Spellman SR, Wael S
2025 | Future Oncology
Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary.
Authors:
de Lima M, Kebriaei P, Lanza F, Cho C, Popradi G, Kaur M, Zhang MJ, Zhang F, Shah R, Vandendries E, Asomaning K, Dorman S, Stelljes M, Marks DI, Saber W
2025 | medRxiv : The Preprint Server for Healt...
Genomics of acute myeloid leukemia at diagnosis and remission.
Authors:
Yu K, Dillon LW, Tettero JM, Gui G, Al-Ali RW, Grunwald MR, Krakow EF, Griffiths EA, Gomez-Arteaga A, Vedula RS, Solh M, Salhotra A, Bejanyan N, Muffly L, Jimenez-Jimenez AM, Drazer MW, Chen YB, Logan A, Jayani-Kosarzycki RV, Balderman SR, Blachly JS, Shaffer BC, Druhan LJ, Yeung CC, Kennedy VE, Fathi AT, Carraway HE, Gurbuxani S, Tjota MY, Sahoo F, Smith M, Barfield D, Guo J, Han J, Hu J, Jo H, Kudlingar V, Li W, Qiu Y, Sathyan P, Truong S, Catreux S, NG S, Luong K, Zhu Y, Bahr R, Diemer J, Ferrone CK, Getker AJ, Bjerke J, Bo-Subait S, Devine SM, Dietel B, Giammarino G, Chihak EH, Kou J, Kolb E, Vitali DO, Spellman SR, Tesch BK, Vogel J, Waldvogel S, Weatherspoon S, Auletta JJ, Hourigan CS
2025 | Blood Advances
Hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report.
Authors:
Alexander JL, Dávila Saldaña BJ, Brazauskas R, Dammalapati SG, Griffith LM, Shah AJ, Shimano KA, Ochs HD, Bleesing J, Ebens CL, Kapadia M, Bauchat A, Kapoor N, Oved JH, Eissa H, Lust H, Keller MD, Haines H, Chandrakasan S, Talano JM, Rayes A, Madden LM, Shereck EB, 24. Miller HK, Forbes Satter LR, Martinez CA, Rozmus J, Bednarski JJ, Yu LC, Chellapandian D, Aquino VM, Knutsen AP, Chong H, Chopek A, Gillio AP, Joshi A, 37. Rangarajan HG, Moore TB, Andolina JR, DeSantes K, Vander Lugt MT, Prockop SE, Shyr D, Sullivan KE, Parikh SH, Weinacht KG, Torgerson TR, Marsh RA, Dvorak CC, Chan AY, Haddad E, Heimall J, Pulsipher MA, Leiding JW, Kohn DB, Puck JM, Notarangelo LD, Rawlings DJ, Cowan MJ, Petrovic A, Pai SY, Burroughs LM
2025 | Statistics in Medicine
Covariate-adjusted group sequential comparisons of survival probabilities.
Authors:
Zhang P, Logan BR, Martens MJ
2025 | Transplantation and Cellular Therapy
Genetic findings of potential donor origin in cells used for cell and gene therapy: Recommendations from the World Marrow Donor Association (WMDA).
Authors:
Pryce A, Cody M, Madbouly A, van Eerden E, Machin LL, Stefanski HE, Hatton D, Anthias C, Hernandez D, Bannon S, Mengling T, Allan DS
2025 | Blood Advances
Outcomes Following Matched Sibling Donor transplantation for severe combined immunodeficiency: A report from the PIDTC.
Authors:
Rayes A, Logan BR, Liu X, Dara J, Buckley RH, Oved JH, Kapoor N, Kapadia M, Chandra S, Martinez CA, Bunin N, Chandrakasan S, Chen K, Bednarski JJ, Haines HL, Eissa H, Talano JM, Keller MD, Ebens CL, Chaudhury S, Shereck EB, Aquino VM, Knuston AP, Alexander JL, Chellapandian D, Shah AJ, Miller HK, Vander Lugt MT, Seroogy CM, Dorsey MJ, Mousallem T, Parrott RE, O'Reilly RJ, Aguayo-Hiraldo PI, Prockop S, Dávila Saldaña BJ, Thakar MS, Burroughs LM, Torgerson TR, Leiding JW, Marsh RA, Griffith LM, Pulsipher MA, Kohn DB, Notarangelo LD, Cowan MJ, Puck JM, Cuvelier GDE, Heimall J, Haddad E, Pai SY, Dvorak CC
2025 | Bone Marrow Transplantation
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia.
Authors:
Al-Ali RW, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong ZC, Huang Y, Gerhold J, Holman M, Jacobsen A, D'Angelo J, Miller J, Elias K, Auletta JJ, El Chaer F, Devine SM, Jimenez AMJ, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Radich JP, Lindsley RC, Dillon LW, Hourigan CS
2025 | Blood Advances
CHARM is prognostic of geriatric morbidity and toxicity after allogeneic transplant for older adults: BMT CTN 1704 study.
Authors:
Artz, AS, Logan, BR, Saber, W, Geller, N, Bellach, A, Kou, J, Wood, WA, McCarty, JM, Knight, TG, Runaas, L, Johnston, L, Walston, J, Nakamura, R, Mishra, A, Uberti, J, Dahi, PB, McCurdy, SR, Saultz, JN, Morris, L, Ismus, P, Hogan, WJ, Nadiminti, K, Bhatt, VR, Olin, R, Maakaron, J, Sobecks, R, Wall, S, Mattila, D, Protz, B, Devine, SM, Horowitz, MM, Sorror, ML
2025 | Transplantation and Cellular Therapy
Access to allogeneic cell transplantation based on donor search prognosis: BMT CTN 1702 trial.
Authors:
Dehn, JG, Logan, BR, Lee, SJ, Shaw, BE, Devine, SM, Ciurea, SO, Horowitz, MM, He, N, Pusic, I, Srour, SA, Arai, S, Juckett, M, Uberti, J, Hill, L, Vasu, S, Hogan, WJ, Hayes-Lattin, B, Westervelt, P, Bashey, A, Farhadfar, N, Grunwald, MR, Leifer, E, Symons, H, Saad, A, Vogel, J, Erickson, C, Buck, K, Pidala, J
2025 | Haematologica
CD19 directed CAR T therapy for intravascular large B-cell lymphoma.
Authors:
Patel J, Gopal A, Cherniawsky H, Ram R, Kamble R, Hamadani M
2025 | Blood Advances
Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry.
Authors:
John S, Curran KJ, Hall EM, Keating AK, Baumeister SHC, Nikiforow S, Driscoll T, Moskop A, McNerney KO, Phillips CL, Pulsipher MA, Hsieh EM, Rouce RH, Pasquini MC, Tiwari R, Willert J, Ramos R, Krueger J, Guest E, Grupp SA
2025 | Transplantation and Cellular Therapy
CRS or ICANS are rare beyond 2 weeks after lisocabtagene maraleucel infusion: Data from clinical trials and the real-world setting.
Authors:
Hunter BD, Lunning MA, Shadman M, Ahmed S, Abramson JS, Perales MA, Ahmed N, Mirza AS, Isufi I, Frigault MJ, Crombie JL, Miklos DB, Vasconcelos A, Crotta A, Bernasconi D, Roy D, Bleickardt E, Pasquini MC, Kamdar M